• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Omnicell Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    5/23/25 4:34:00 PM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    false 0000926326 0000926326 2025-05-21 2025-05-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D. C.  20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
    1934

     

    Date of Report (Date of earliest event reported): May 21, 2025

     

    OMNICELL, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   000-33043   94-3166458
    (State or other jurisdiction of
    incorporation)
     

    (Commission File Number)

     

    (IRS Employer Identification Number)

     

    4220 North Freeway

    Fort Worth, TX 76137

    (Address of principal executive offices, including zip code)

     

    (877) 415-9990

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  Trading Symbol  Name of each exchange on which registered
    Common Stock, $0.001 par value  OMCL  NASDAQ Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    Amendment to the Omnicell, Inc. 2009 Equity Incentive Plan

     

    As described below under Item 5.07 of this Current Report on Form 8-K, at the 2025 Annual Meeting of Stockholders of Omnicell, Inc. (the “Company”) held on May 21, 2025 (the “Annual Meeting”), the Company’s stockholders approved an amendment to the Company’s 2009 Equity Incentive Plan, as amended (as amended, the “Amended 2009 Plan”), which, among other items, added an additional 1,750,000 shares to the number of shares of common stock authorized for issuance under the Amended 2009 Plan.

     

    The Amended 2009 Plan is described in detail in Proposal No. 3 in the Company's Definitive Proxy Statement on Schedule 14A filed with the United States Securities and Exchange Commission on April 3, 2025 (the “Proxy Statement”), and the full text of the Amended 2009 Plan is attached to the Proxy Statement as Appendix A. The description of the Amended 2009 Plan set forth above is a summary only and is qualified in its entirety by reference to the full text of the Amended 2009 Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders

     

    On May 21, 2025, the Company held its Annual Meeting. Four items of business, which were described in detail in the Proxy Statement, were acted upon by the stockholders at the Annual Meeting. The final voting results regarding each proposal are set forth below.

     

    Proposal No. 1: Election of Three Class III Directors to Hold Office Until the 2028 Annual Meeting of Stockholders

     

    Edward P. Bousa, Mary Garrett, and Bruce E. Scott were elected to serve as members of the Company’s Board of Directors (the “Board”) until the 2028 Annual Meeting of Stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal.

     

    Votes were cast as follows for the election of directors:

     

       For  Withheld  Broker Non-Votes
    Edward P. Bousa  35,421,552  2,264,612  4,279,972
    Mary Garrett  34,722,222  2,963,942  4,279,972
    Bruce E. Scott  34,114,987  3,571,177  4,279,972

     

    Proposal No. 2: Advisory Vote to Approve Named Executive Officer Compensation

     

    The stockholders voted, on an advisory basis, to approve named executive officer compensation by the following vote:

     

    For  Against  Abstain  Broker Non-Votes
    35,780,985  1,724,508  180,671  4,279,972

     

    Proposal No. 3: Approval of an Amendment to the Omnicell, Inc. 2009 Equity Incentive Plan, as Amended

     

    The stockholders voted to approve the Amended 2009 Plan to, among other items, add an additional 1,750,000 shares to the number of shares of common stock authorized for issuance under the Amended 2009 Plan, by the following vote:

     

    For  Against  Abstain  Broker Non-Votes
    35,600,671  1,915,066  170,427  4,279,972

     

     

     

     

    Proposal No. 4: Ratification of the Selection of Independent Registered Public Accounting Firm

     

    The stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025 by the following vote:

     

    For  Against  Abstain
    41,527,276  166,260  272,600

     

    Item 9.01. Financial Statements and Exhibits

     

    (d) Exhibits.

     

    Exhibit
    Number
      Description of Document
    10.1   Omnicell, Inc. 2009 Equity Incentive Plan, as amended (incorporated by reference to Appendix A to Omnicell, Inc.’s definitive proxy statement on Schedule 14A for the Omnicell, Inc. 2025 Annual Meeting of Stockholders held May 21, 2025 (File No. 000-33043))*
         
    104   Cover Page Interactive Data File (embedded within the inline XBRL document)

     

    * Indicates a management contract, compensation plan, or arrangement.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      OMNICELL, INC.
       
    Date: May 23, 2025 /s/ Corey J. Manley
      Corey J. Manley
      Executive Vice President and Chief Legal and Administrative Officer

     

     

     

    Get the next $OMCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings